首页 | 本学科首页   官方微博 | 高级检索  
     

Romidepsin:治疗皮肤T细胞淋巴瘤的新药
引用本文:张静,刘俏,彭六保,易利丹,阳巧凤,曾小慧. Romidepsin:治疗皮肤T细胞淋巴瘤的新药[J]. 中国新药与临床杂志, 2011, 0(1)
作者姓名:张静  刘俏  彭六保  易利丹  阳巧凤  曾小慧
作者单位:中南大学湘雅二医院药学部;中南大学药学院;
摘    要:Romidepsin是一种新的组蛋白去乙酰化酶抑制剂,可引起组蛋白超乙酰化,使细胞周期停滞,造成某些肿瘤细胞株程序性凋亡。在美国该药已被批准用于治疗先前曾接受过至少1种系统治疗的皮肤T细胞淋巴瘤患者。本文从romidepsin的研发背景、药理学、临床研究以及安全性评价等方面进行系统的概述,以推动romidepsin的进一步应用和研究。

关 键 词:romidepsin  淋巴瘤,T细胞,皮肤  组蛋白去乙酰酶抑制剂  药理学,临床

Romidepsin:a new therapy for cutaneous T-cell lymphoma
ZHANG Jing,LIU Qiao. Romidepsin:a new therapy for cutaneous T-cell lymphoma[J]. Chinese Journal of New Drugs and Clinical Remedies, 2011, 0(1)
Authors:ZHANG Jing  LIU Qiao
Affiliation:ZHANG Jing~(1,2),LIU Qiao~(1,PENG Liu-bao~1,YI Li-dan~(1,YANG Qiao-feng~(1,ZENG Xiao-hui~(1,2) (1.Department of Pharmacy,the Second Xiangya Hospital of Central South University,Changsha HU-NAN 410011,China,2.Pharmacy of Central South University,Changsha HU-NAN 410013,China)
Abstract:Romidepsin is a new histone deacetylase(HDAC) inhibitor which causes the accumulation of acetylated histones,and induces cell cycle arrest and apoptosis of some cancer cell lines.Romidepsin is recently approved for the treatment of cutaneous T-cell lymphoma(CTCL) patients who have received at least one prior systemic therapy in USA.This review outlines the background of the discovery,pharmacology, clinical studies and safety evaluation of romidepsin in order to make some contribution to further application ...
Keywords:romidepsin  lymphoma  T-cell  cutaneous  histone deacetylase inhibitor  pharmacology  clinical  
本文献已被 CNKI 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号